Charles is a Research Analyst at Fisher Investments and has been with the firm since 2012. He previously worked in the Trading Department where he executed equity and fixed income trades in over 40 different markets around the world. Charles graduated from Cal Poly San Luis Obispo with a Bachelor’s degree in Economics and an MBA.
While the debate is far from over, the early rumblings suggest to us potential drug price reform isn’t likely to materially affect Pharmaceuticals stocks.
The Trump administration’s proposals for lowering prescription drug prices aren’t nearly as ambitious as investors feared and likely won’t happen in their current form.
